Assessment of the safety and effectiveness of neoadjuvant camrelizumab and apatinib in conjunction with chemotherapy for stage IIIA (N2) non-small cell lung cancer: Results from a multi-center, single-arm phase II study - Summary - MDSpire

Assessment of the safety and effectiveness of neoadjuvant camrelizumab and apatinib in conjunction with chemotherapy for stage IIIA (N2) non-small cell lung cancer: Results from a multi-center, single-arm phase II study

  • By

  • Lilan Zhao

  • Tianxing Guo

  • Yi Zhang

  • Zhen Huang

  • Yangyun Huang

  • Lihuan Zhu

  • Xing Chen

  • Nan Zhang

  • Liren Guo

  • Rongzhi Huang

  • Guojun Geng

  • Ning Li

  • Shuxing Chen

  • Xiaojie Pan

  • Wenshu Chen

  • October 24, 2025

  • 0 min

Share

Objective:

To evaluate the safety and efficacy of an innovative neoadjuvant therapy combining camrelizumab, apatinib, and chemotherapy in patients with resectable stage IIIA (N2) non-small cell lung cancer (NSCLC).

Key Findings:
  • The combination therapy demonstrated an acceptable safety profile.
  • Efficacy outcomes, including tumor shrinkage and surgical feasibility, were assessed through imaging and multidisciplinary evaluations, with specific metrics to be detailed.
Interpretation:

The study suggests that the combination of camrelizumab, apatinib, and chemotherapy may provide a promising neoadjuvant treatment strategy for patients with stage IIIA (N2) NSCLC, although further studies, particularly larger trials, are needed to fully establish its efficacy.

Limitations:
  • Single-arm design limits comparison with control groups.
  • Results may not be generalizable beyond the study population.
  • Potential biases related to participant selection and treatment adherence.
Conclusion:

Neoadjuvant therapy with camrelizumab and apatinib in conjunction with chemotherapy shows potential for improving outcomes in stage IIIA (N2) NSCLC, warranting further investigation.

Original Source(s)

Assessment of the safety and effectiveness of neoadjuvant camrelizumab and apatinib in conjunction with chemotherapy for stage IIIA (N2) non-small cell lung cancer: Results from a multi-center, single-arm phase II study

  • by Lilan Zhao, Tianxing Guo, Yi Zhang, Zhen Huang, Yangyun Huang, Lihuan Zhu, Xing Chen, Nan Zhang, Liren Guo, Rongzhi Huang, Guojun Geng, Ning Li, Shuxing Chen, Xiaojie Pan, Wenshu Chen

  • October 24, 2025

Related Content

MRI perfusion in evaluating ovarian masses: diagnostic performance of wash out rate

Validation of a cervical CDO1/CELF4 methylation test for endometrial cancer: a prospective paired-sample comparison with intrauterine specimen

Percutaneous nephrostomy as a marker of clinical vulnerability in non-metastatic muscle-invasive bladder cancer: prognostic and infectious implications